CoChat

Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor

Open access
Cordero, Toni L., Dai, Zheng, Arrieta, Arcelia, Niu, Fang, Vella, Melissa, Shin, John, Rhinehart, Andrew S., McVean, Jennifer, Lee, Scott W., Slover, Robert H., Forlenza, Gregory P., Shulman, Dorothy I., Pop-Busui, Rodica, Thrasher, James R., Kipnes, Mark S., Christiansen, Mark P., Buckingham, Bruce A., Pihoker, Catherine, Sherr, Jennifer L., Kaiserman, Kevin B., Vigersky, Robert A., for the MiniMed™ AHCL Study Group · 2023 · Diabetes Technology & Therapeutics
Cited by 30

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Background: Safety and significant improvement in overall glycated hemoglobin (A1C) and percentage of time spent in (TIR), below (TBR), and above (TAR) glucose range were demonstrated in the pivotal trial of adolescents and adults using the MiniMed™ advanced hybrid closed-loop (AHCL) system with the adjunctive, calibration-required Guardian™ Sensor 3. The present study evaluated early outcomes of continued access study (CAS) participants who transitioned from the pivotal trial investigational system to the approved MiniMed™ 780G system with the non-adjunctive, calibration-free Guardian™ 4 Sensor (MM780G+G4S). Study data were presented alongside those of real-world MM780G+G4S users from Europe, the Middle East, and Africa. Methods: The CAS participants ( N = 109, aged 7–17 years and N = 67, aged >17 years) used the MM780G+G4S for 3 months and data of real-world MM780G+G4S system users ( N = 10,204 aged ≤15 years and N = 26,099 aged >15 years) were uploaded from September 22, 2021 to December 02, 2022. At least 10 days of real-world continuous glucose monitoring (CGM) data were required for analyses. Glycemic metrics, delivered insulin and system use/interactions underwent descriptive analyses. Results: Time in AHCL and CGM use were >90% for all groups. AHCL exits averaged 0.1/day and there were few blood glucose measurements (BGMs) (0.8/day–1.0/day). Adults in both cohorts met most consensus recommendations for glycemic targets. Pediatric groups met recommendations for %TIR and %TBR, although not those for mean glucose variability and %TAR, possibly due to low use of recommended glucose target (100 mg/dL) and active insulin time (2 h) settings (28.4% in the CAS cohort and 9.4% in the real-world cohort). The CAS pediatric and adult A1C were 7.2% ± 0.7% and 6.8% ± 0.7%, respectively, and there were no serious adverse events. Conclusions: Early clinical use of the MM780G+G4S was safe and involved minimal BGMs and AHCL exits. Consistent with real-world pediatric and adult use, outcomes were associated with achievement of recommended glycemic targets. Clinical Trial Registration number: NCT03959423

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2023.0123

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 30

Metadata

Authors
Cordero, T. L., Dai, Z., Arrieta, A., Niu, F., Vella, M., Shin, J., Rhinehart, A. S., McVean, J., Lee, S. W., Slover, R. H., Forlenza, G. P., Shulman, D. I., Pop-Busui, R., Thrasher, J. R., Kipnes, M. S., Christiansen, M. P., Buckingham, B. A., Pihoker, C., Sherr, J. L., Kaiserman, K. B., Vigersky, R. A., & for the MiniMed™ AHCL Study Group
Venue
Diabetes Technology & Therapeutics
Published
2023-09-01
Volume
25
Issue
9
Pages
652-658
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W4378746521
Cited by
30
References
16
FWCI
4.96
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. https://app.cochat.ai/papers/10.1089/dia.2023.0123
The paper
Cordero, T. L., Dai, Z., Arrieta, A., Niu, F., Vella, M., Shin, J., Rhinehart, A. S., McVean, J., Lee, S. W., Slover, R. H., Forlenza, G. P., Shulman, D. I., Pop-Busui, R., Thrasher, J. R., Kipnes, M. S., Christiansen, M. P., Buckingham, B. A., Pihoker, C., Sherr, J. L., . . . for the MiniMed™ AHCL Study Group. (2023). Glycemic Outcomes During Early Use of the MiniMed™ 780G Advanced Hybrid Closed-Loop System with Guardian™ 4 Sensor. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2023.0123

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.